

January 15, 2020

The Manager	The Manager - Listing Department
Corporate Relationship Department	National Stock Exchange of India Limited
Bombay Stock Exchange Limited	Exchange Plaza, 5th Floor
Floor 25, Phiroze Jeejeebhoy Tower	Plot No. C/1, G Block,
Dalal Street, Mumbai-400001	Bandra Kurla Complex,
	Bandra(E), Mumbai-400051
BSE Scrip Code: 532341	NSE Symbol: IZMO

Dear Sir/Ma'am,

Subject: Intimation pursuant to Regulation 40(7) read with Schedule VII- Transfer of Securities and SEBI Circular SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated November 06, 2018.

Pursuant to Regulation 40(7) read with Schedule VII- Transfer of Securities, SEBI Circular SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 dated November 06, 2018-Standardised norms for transfer of securities in physical mode, SEBI Circular SEBI/HO/MIRSD/RTAMB/CIR/P/2020/166 dated September 07, 2020- Re-lodgement of Transfer Requests Shares and SEBI Circular SEBI/HO/MIRSD/RTAMB/CIR/P/2020/236 dated December 02, 2020- Operational guidelines for Transfer and Dematerialization of relodged physical shares, the company has received request from a shareholder to transfer shares held in physical mode as per details mentioned below:

Folio Number	Seller Name (Transferor)	Certificate No	Distinction Number (FROM)	Distinction Number (TO)	Shares	Buyer Name (Transferee)	
00001914	SHITAL B SHAH	24170	3897901	3898000	100	DOSHI SUHAG H	
00001898	NIKITA ASHOK MAHESHWARI	10964	3896301	3896400	100		

Pursuant to aforesaid circular, we submit herewith copies of Newspaper Advertisement Published in "Financial Express" (English Edition) and "Vartha Bharati" (Kannada Edition) on January 15th, 2020 and the same is also available on the website of the Company, i.e.

Phone: +91 80 67125400

Email: info@izmoltd.com

: +91 80 67125408

Fax

www.izmoltd.com

CIN: L72200KA1995PLC018734

Kindly take this information on your records.

Yours faithfully,

For IZMO Limited

Danish Reza

Company Secretary and Compliance Officer

Enc: As Above

FINANCIAL EXPRESS

COVID-19 VACCINE

India to treat homegrown vaccine same as AstraZeneca's

REUTERS New Delhi, January 14

INDIA WILL TREAT a domestic Covid-19 vaccine "equally" with a prominent global one, even though the homegrown drug's efficacy has not been proven, and people will have no choice which one they get, a top government vaccine official told Reuters.

The government on Saturday will launch one of the world's biggest vaccination programmes with shots manufactured in India — one developed by Oxford University and AstraZeneca, the other by Bharat Biotech International with a state-run institute.

Bharat Administering Biotech's COVAXIN, a move cheered by nationalist politicians, has worried some health experts who consider it rushed, as the vaccine has only limited, "clinical-trial mode" approval. In addition to efficacy concerns, the close monitoring required for its use will be a massive challenge in a country of 1.35 billion people.

Controversy over COVAXIN

similar to what China and

Russia faced for pushing

Vinod K. Paul, who heads a government panel on vaccine strategy, said in an interview. They excite immunity against the

Indian health advocacy

groups, watchdogs and

opposition politicians have

questioned the local

vaccine's approval, which

came just a day after the

authorities asked

Hyderabad-based Bharat

Biotech for more evidence

it would work

through their own shots be-

fore their efficacy was known

risks undermining India's

position as the vaccine capital

of the world, medical ethics

the other - both vaccines are

equally important, both vac-

cines are hugely immunogenic,"

"No vaccine is a backup to

groups say.

"There is no choice to the individual at this point of time" as India ramps up production of the vaccines, he said.

This marks the government's clearest statement that recipients may not choose their vaccine. The health secretary said this week that no other country allows a choice but stopped short of saying India would do the same.

Experts at India's drug regulator this month recommended stricter monitoring for COV-AXIN, as is done during clinical trials, especially if cases of infection by mutant strains of the virus spread fast. At the same time, the government wants to inoculate as many people as possible as demand for vaccines outstrips supply.

Indian health advocacy groups, watchdogs and opposition politicians have questioned the local vaccine's approval, which came just a day after the authorities asked Hyderabadbased Bharat Biotech for more evidence it would work.

"This achievement will indeed be hailed as a major Indian scientific achievement once efficacy data are released, but by this hasty approval without evidence, the government has shot itself in the foot," the All-India People's Science Network, a network of science advocacy groups, said in a statement.

"Whatever prestige India may gain abroad for an indigenously developed vaccine will be outweighed by the damage caused to the credibility of CO-VAXIN in particular, and of Indian science, research and regulatory institutions."

Paul defended moving ahead with the drug, which Bharat Biotech developed with the Indian Council of Medical Research, saying all Covid-19 vaccines in the world, including those by Pfizer Inc and Moderna Inc, are administered under emergency authorisation.

"The scientific rigour under the circumstances of the pandemic has been respected in a robust manner," Paul said. "There is no pressure" on India's regulator, the Central Drugs Standard Control Organization.

Group of experts slams critics of India's approval process for Covid vaccines

PRESS TRUST OF INDIA New Delhi, January 14

AGROUP OF doctors and scientists on Thursday hit out at the critics of the government's approval to two Covid-19 vaccines, especially the one produced indigenously by Bharat Biotech, alleging that their "reprehensible"utterances are causing huge credibility crisis for the Indian scientific community.

In a statement signed by 45 medical professionals and scientists, the group expressed shock at the "irresponsible statements of vested interests" and accused these critics of casting aspersions on Indian ex-

In a statement signed by 45 medical professionals and scientists, the group expressed shock at the "irresponsible statements of vested interests"

perts' integrity by making politicised statements to doubt the recent research in the field of Covid-19 vaccines.

The statement, whose signatories include former AIIMS directors T D Dogra and M C Mishra, former CSIR-IICT, Hyderabad, chief scientist A Gangagni Rao and Manipal Education and Medical Group's

Chairman of Board Ranjan Pai, said these vaccines are our gift to the humanity. India had recently approved

two vaccines, Oxford-Astra Zeneca's Covishield being manufactured by Serum Institute of India and Bharat Biotech's Covaxin, for emergency-use authorisation. Some experts and a few opposition leaders had questioned the decision, noting that the phase three trial of Covaxin was not yet complete and its efficacy data was not available.

The government has insisted that it has followed all procedure. "We urge upon our fellow countrymen to reject the manipulations of vested inter-

ests aimed at politicisation and defamation of our nation's scientists, doctors and scientific community for their narrowvested interests. They need to realise that by doing so, these vested interests are wrecking the highly valued and credible scientific edifice created by us, which has made India a global leader in the export of vaccines," the statement said.

"Such reprehensible utterances are causing huge credibility crisis for the Indian scientific community who have devoted their lifetimes to make India a name to reckon with in export of vaccines all over the world," it added.

PM to launch vaccination drive tomorrow

PRESS TRUST OF INDIA New Delhi, January 14

PRIME MINISTER NARENDRA Modi will launch the rollout of India's Covid-19 vaccination programme on January 16, the Union Health Ministry said on Thursday.

He is likely to interact via video link with some healthcare workers from across the country who will be receiving the shots on the first day, according to sources. Modi is also likely to launch the Co-WIN (Covid Vac-



a digital platform created for real-time monitoring of Covid-19 vaccine delivery and distribution, they said.

The health ministry said,

"The massive countrywide Covid-19 vaccination drive will be rolled out by Prime Minister from January 16. This would be the world's largest immunisation exercise. Therefore, it has been decided by the Ministry of Health in consultation with the office of the President of India to reschedule the Polio vaccination day, also known as the National Immunisation Day (NID) or 'Polio Ravivar' to 31st January."

Each vaccination session will cater to a maximum of 100 beneficiaries.

Mumbai airport facilitates delivery of 29L **Covishield doses**

MUMBAI AIRPORT ON Thursday said it has facilitated cumulative delivery of 29,28,000 doses of Covishield vaccine across 25 destinations in the country since Wednesday. The city's Chhatrapati Shiv-

aji Maharaj International Airport (CSMIA) started handling flights carrying Covid-19 vaccines from January 13. —PTI

New consumer rights rules may hit rooftop solar capacity addition

VIKAS SRIVASTAVA Mumbai, January 14

THE LATEST RULES regarding the consumer rights laid down by the Union power ministry is seen to impede the pace of capacity addition of the rooftop solar in the country by disincentivising commercial and industrial users from installing such power generation capacities in their premises.

While such consumers were earlier earning around ₹7/unit by selling the surplus power generated from their rooftop solar plants to the state-run power distribution companies (discoms), under the new mandate they will be billed through "gross metering", and compensated at rates close to the average power purchase cost of discoms which ranges around ₹3.5–₹4/unit.

The national solar energy federation of India has requested power minister RK Singh to amend the provision on gross metering for larger rooftop consumers, pointing out that "investment to the tune of ₹1,500 – 2,000 crore is either under contract or under commissioning phase" for such rooftop capacities and the new mandate "will create uncertainty and impact the ongoing projects".

Out of the total solar capacity of 36,910 MW, only 3,402 MW currently comes from rooftop solar. The government aims to have 40,000 MW of rooftop solar capacity by 2022.

At present, the commercial

and industrial consumers with rooftop solar capacities export anywhere between 5-50% of solar power generated during the day to discoms at prevailing retail rates. However, after coms, low paying consumers the new provisions are implemented, the return of investors in rooftop plants will significantly reduce, giving them no reason to spend



money on installing rooftop solar plants.

"If the government does not provide the export provision under the new rules, going ahead hardly 100-150 MW of rooftop power will get added to the system against 600 MW that we saw in 2020, completely negating the growth of the industry players and increasing the client payback time from 3-4 years to six years at least," Puneet Goyal, founder of solar firm SunAlpha, told FE.

Almost 85-90% of the new capacities that would have come to commercial and industrial segment will be completely wiped out because of gross metering provisions, Goyal added.

The new provisions are seen to help the ailing staterun discoms which are reluctant to let go of their higherpaying commercial and industrial consumers.

"It is a balancing act as net metering for commercial and industrial users will ultimately result in higher tariffs for the residential consumers," a senior discom official told FE on conditions of anonymity. "When high-paying commercial and industrial users start buying less power from dislike residential customers will end up paying more," the person added.

(with inputs from Anupam Chatterjee in New Delhi)

IZMO Limited

CIN-L72200KA1995PLC018734

Regd. Off: #177/2C, Billekahalli Industrial Area, Bannerghatta Road, Bengaluru-560 076. e-mail:info@izmoltd.com www.izmoltd.com

NOTICE NOTICE is hereby given that pursuant to SEBI circular SEBI/HO/MIRSD/DOS3/CIR/P/2018/139

dated November 06, 2018, Company has received request from a shareholder (herein called as

"Transferee") to transfer the shares that are held in the name of the other shareholders

(herein called as "Transferor") as detailed below. These shares were claimed to be purchased by

Any person, who claims the ownership of above mentioned shares, should contact the Company

by e-mail at company.secretary@izmoltd.com and/or can sent post at Registered office address

within 30 days from the date of aforesaid notice along with appropriate documentary evidence in

Dist Nos

(FROM)

3897901

3896301

Dist Nos

(TO)

3898000

3896400

Shares

100

100

Certificate

24170

10964

shares will be transferred in favour of Transferee without any further intimation.

the shareholders and could not transferred in their name.

Seller Name

(Transferor)

SHITAL B SHAH

NIKITA ASHOK

MAHESHWARI

HC refuses to extend I-T returns filing date

FE BUREAU New Delhi, January 14

THE GUJARAT HIGH Court has rejected a plea seeking further extension of the due date for the filing of income tax (I-T) returns by businesses and professionals covered under the Section 44AB of the I-T Act from February 15 to March 31.

"We have concluded that we should not interfere in the matter," the Court said hearing a special civil application by the All-Gujarat Federation of Tax Consultants."In the result, bot the writ applications fail and are hereby rejected. At this stage, we may only observe that the CBDT may consider issuing an appropriate circular taking a lenient view as regards the consequences of late filing of the Tax Audit Reports as provided under Section 271B of the Act. We leave it to the better discre-

tion of the CBDT in this regard." An assessee needs to be audited under Section 44AB if annual turnover/receipts in business exceed ₹1 crore while it is ₹50

lakh in case of professionals. In case of failure to get accounts audited, the Income Tax Act section 271B prescribes that the Assessing Officer may direct that such person shall pay, by way of penalty, a sum equal to onehalf per cent of the total sales, turnover or gross receipts, as the case may be, in business, or of the gross receipts in the profession, in such previous year or years or a sum of $\mathbb{7}1,50,000$, whichever is less.

Due to Covid-19 pandemic, the due dates for filing of return/tax audit have already been extended on three occasions. The latest extension is from January 31 to February 15 for assesses whose accounts need to be audited under Section 44AB.



Funded ₹ 3.59 trillion[^] to Ministry of Railways for progress of the Nation

- IRFC Dedicated market borrowing arm for Indian Railways
- Registered with RBI as a Systemically Important NBFC-ND-IFC
- Funded acquisition of 11,670 locomotives, 66,603 passenger coaches and 244,902 freight wagons*
- Total revenue from operations increased by 22.15% between Fiscal 2019-2020
- Zero non-performing assets and Capital Adequacy Ratio of 433.92%* Rolling Stock Assets worth ₹ 2,346,271.68 million*
- Capital expenditure of ₹ 8,560.20 billion planned for Fiscal 2016-2020

by the Indian Railways#

^Cumulative funding of ₹ 3,592.75 billion as of September 30, 2020. *As of September 30, 2020. #Source: Reform, Perform and Transform – Report by the Indian Railways, July 2017. Indian Railway Finance Corporation Limited is proposing, subject to applicable statutory and regulatory requirements, receipt of requisite approvals, market conditions and other considerations, to undertake an initial public offer of its Equity Shares and has filed the RHP with the Registrar of Companies, National Capital Territory of Delhi and Haryana at New Delhi. The RHP is available on the websites of SEBI, BSE and NSE at www.sebi.gov.in, www.bseindia.com and www.nseindia.com, respectively, and on the websites of the BRLMs i.e. DAM Capital Advisors Limited (Formerly known as IDFC Securities Limited), HSBC Securities and Capital Markets (India) Private Limited, ICICI Securities Limited and SBI Capital Markets Limited at www.damcapital.in, https://www.business.hsbc.co.in/en-gb/in/generic/ipo-open-offer-and-buyback, www.icicisecurities.com and www.sbicaps.com, respectively. Potential investors should note that investment in equity shares involves a high degree of risk and for details relating to such risk, see the section titled "Risk Factors" on page 24 of the RHP. Potential investors should not rely on the DRHP or Addendum dated October 23, 2020 filed with SEBI for making any investment decision.

The Equity Shares have not been and will not be registered under the U.S. Securities Act of 1933, as amended ("Securities Act") or any other applicable law of the United States and, unless so registered, may not be offered or sold within the United States, except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and applicable U.S. state securities laws. Accordingly, the Equity Shares are being offered and sold (i) within the United States only to persons reasonably believed to be "qualified institutional buyers" (as defined in Rule 144A and referred to in the RHP as "U.S. QIBs". For the avoidance of doubt, the term "U.S. QIBs" does not refer to a category of institutional investor defined under applicable Indian regulations and referred to in the RHP as "QIBs") in transactions exempt from, or not subject to, the registration requirements of the Securities Act, and (ii) outside the United States in offshore transactions in reliance on Regulation S and pursuant to the applicable laws of the jurisdictions where those offers and sales are made. There will be no public offering in the United States.

support of such claim. If the Company fails to receive any claims within the said period, such For IZMO Limited sd/-Danish Reza

financialexp.ep.m.in

Place: Bengaluru

Date: 11.01.2021

Folio

Number

'00001914

'00001898

Company Secretary

Buyer Name

(Transferee)

DOSHI

SUHAG H

INDIAN RAILWAY FINANCE

CORPORATION LIMITED

(A Government of India Enterprise)

www.irfc.nic.in

BENGALURU



ಇಜ್ಮೋ ಲಿಮಿಟೆಡ್

CIN-L72200KA1995PLC018734

ನೋಂದಾಯಿತ ಕಛೇರಿ: ನಂ.177/2ಸಿ, ಬಿಳೇಕಹಳ್ಳಿ ಕೈಗಾರಿಕಾ ಪ್ರದೇಶ, ಬನ್ನೇರುಘಟ್ಟ ರಸ್ತೆ, ಬೆಂಗಳೂರು-560076, E-Mail: info@izmoltd.com www.izmoltd.com

ಸೂಚನೆ

ಸೆಬಿ ಸುತ್ತೋಲೆ ಸಂ. SEBI/HO/MIRSD/DOS3/CIR/P/2018/139 ದಿನಾಂಕ 06.II.2018 ಪ್ರಕಾರ ಕೆಳಕಂಡ ಷೇರುದಾರರಿಂದ ಕಂಪನಿಯು ಷೇರುದಾರರ ಹೆಸರಿನಲ್ಲಿರುವ ಷೇರುಗಳನ್ನು ಅವರ ಹೆಸರಿಗೆ ವರ್ಗಾಯಿಸಲು ಕೋರಿರುತ್ತಾರೆ ಎಂದು ಈ ಸೂಚನೆ ಮೂಲಕ ತಿಳಿಸುತ್ತಿದ್ದೇವೆ. ಈ ಷೇರುಗಳನ್ನು ಷೇರುದಾರರು ಖರೀದಿಸಿದ್ದಾರೆ ಮತ್ತು ಅವರ ಹೆಸರಿನಲ್ಲಿ ವರ್ಗಾಯಿಸಲು ಸಾಧ್ಯವಾಗುವುದಿಲ್ಲ.

ಫೋಲಿಯೋ ಸಂಖ್ಯೆ	ಮಾರಾಟಗಾರರ ಹೆಸರು ವರ್ಗಾವಣೆದಾರರು	ಸರ್ಟಿಫಿಕೇಟ್ ಸಂಖ್ಯೆ		ಡಿಸ್ಟ್ರಿಬ್ಯೂಟ್ ಸಂ.(ವರೆಗೆ)		ಖರೀದಿದಾರರ ಹೆಸರು (ವರ್ಗಾವಣೆ)	
00001914	ಶೀತಲ್ ಬಿ ಶಾ	24170	3897901	3898000	100	ದೂಷಿ ಸುಹಾಗ್ ಹೆಚ್	
'00001898	ನಿಖಿತಾ ಅಶೋಕ್ ಮಹೇಶ್ವರಿ	10964	3896301	3896400	100		

ಮೇಲೆ ತಿಳಿಸಿದ ಷೇರುಗಳಿಗೆ ಸಂಬಂಧಿಸಿದಂತೆ ಹಕ್ಕು ಹೊಂದಿರುವ ಯಾವುದೇ ವ್ಯಕ್ತಿ, ಈ ದಿನಾಂಕದಿಂದ 30 ದಿನಗಳ ಒಳಗೆ ಕಂಪನಿ ಇ–ಮೇಲ್: company.secretary@izmoltd.com ಮೂಲಕ ಸಂಪರ್ಕಿಸಬಹುದು ಅಥವಾ ನೋಂದಾಯಿತ ಕಚೇರಿಯಲ್ಲಿ ಕಂಪನಿಯೊಂದಿಗೆ ಅಂತಹ ಹಕ್ಕನ್ನು ಸಲ್ಲಿಸಬೇಕು ಮತ್ತು ಅಂತಹ ಹಕ್ಕನ್ನು ಬೆಂಬಲಿಸಲು ಸೂಕ್ತವಾದ ಸಾಕ್ಷ್ಮಚಿತ್ರ ಸಾಕ್ಷ್ಮಗಳೊಂದಿಗೆ ಕಂಪನಿಯು ಸೆಕ್ಯೂರಿಟಿಗಳನ್ನು ವರ್ಗಾಯಿಸಲು ಪ್ರಸ್ತಾಪಿಸಿದೆ ಯಾವುದೇ ಹೆಚ್ಚಿನ ಮಾಹಿತಿ ಇಲ್ಲದೆ ಖರೀದಿದಾರರ ಪರವಾಗಿ. ತಿಳಿಸಿದ ಅವಧಿಯಲ್ಲಿ ಯಾವುದೇ ಹಕ್ಕುಗಳನ್ನು ಪಡೆಯಲು ಕಂಪನಿಯು ವಿಫಲವಾದರೆ, ಅಂತಹ ಷೇರುಗಳನ್ನು ಯಾವುದೇ ಮಾಹಿತಿಯಿಲ್ಲದೆ ವರ್ಗಾವಣೆದಾರರ ಪರವಾಗಿ ವರ್ಗಾಯಿಸಲಾಗುತ್ತದೆ.

ಸ್ಥಳ: ಬೆಂಗಳೂರು ದಿನಾಂಕ: 11.01.2021 ಇಜ್ಮೊ ಲಿಮಿಟೆಡ್ ಪರವಾಗಿ ಸಹಿ/− ಡ್ಯಾನಿಶ್ ರೆಝಾ ಕಂಪನಿ ಕಾರ್ಯದರ್ಶಿ